Amyris (company)
Amyris, Inc. is a biotechnology company headquartered in Emeryville, California. Amyris's products include ingredients for cosmetics, flavors, and fragrances. Amyris owns three brands: Biossance and Pipette, for beauty and baby skincare, and Purecane, a sugar substitute. The company went public on NASDAQ on September 28, 2010 (AMRS).[1]
![]() | |
Public | |
Traded as | NASDAQ: AMRS Russell 2000 Index component |
Industry | Renewable Fuels, Anti-Malaria, Renewable Chemicals, Renewable Products |
Founded | 2003 |
Headquarters | Emeryville, California, USA |
Key people | John Melo: CEO Joel Cherry: President Kathleen Valiasek: CFO Eduardo Alvarez: COO Nicole Kelsey: Gen.Counsel & Secretary |
Revenue | ![]() |
Number of employees | 300–350 |
Website | www |
Artemisinin
Artemisinin is a compound naturally found in the Chinese sweet wormwood plant effective in the treatment of malaria. Its production is hampered by difficult climate and agricultural conditions. Institute for OneWorld Health received a grant from the Bill and Melinda Gates Foundation to develop and produce non-seasonal, high-quality, affordable artemisinin, and engaged Amyris Biotechnologies and Sanofi to assist on certain parts of the project, which is near completion, based on technology from UC Berkeley, NRC Canada, and other sources.
Media coverage
- Using Microbes to create the Next Generation of Fuels on CNN The Next List (February 2013)
- A Better Biofuel on MIT Technology Review (April 2007)
- Bets on Biotech on US News (November 2006)
References
- "Amyris, Inc. Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell". www.nasdaq.com. Retrieved 2020-06-30.